MCL1 and acute myeloid leukemia: Combination treatment of ONO-7475 with venetoclax exhibited potent cytotoxicity against FLT3-mutant AML cell lines and primary cells, including those resistant to venetoclax, particularly those overexpressing MCL-1 [140].